- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03957707
Sterotactische operatie geïntegreerd met trombolyse bij evacuatie van basale ganglionbloedingen (SOITBE)
Sterotactische operatie geïntegreerd met trombolyse bij evacuatie van basale ganglionbloeding: een gerandomiseerde gecontroleerde studie.
Spontaneous cerebral hemorrhage is one of the main causes of death and disability all over the world, accounting for 20%-30% of all cerebrovascular diseases. Minimally invasive surgery of cerebral hemorrhage, especially puncture aspiration, can improve early and long-term neurological recovery in patients with cerebral hemorrhage. Until now, no standardized practice for minimally invasive surgery of spontaneous cerebral hemorrhage has been established. Hematoma puncture and drainage based on CT scans without precise localization and personalized approach design, which may lead to poor efficacy and high risk of complications. Our hospital has much experience in treating cerebral hemorrhage with stereotactic puncture and aspiration. So we conduct a prospective multicenter randomized controlled clinical trial to determine the therapeutic effects of puncture aspiration plus thrombolysis treatment for the perioperative and long-term recovery of patients with small to moderate hematoma in deep basal ganglia via computerized precision coordinates and personalized approach design.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- the Second Affiliated Hospital of Zhejiang University School of Medicine
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Diagnosis of spontaneous basal ganglia hemorrhage by imaging (CT, CTA, etc.) with a hematoma volume of 10-30 mL calculated by ABC/2 formula and Glasgow Coma Scale score ≥ 9.
- With dysfunction such as hematoma-related motor aphasia, sensory aphasia, hemiplegic limb muscle strength ≤ grade 3 or NIHSS score ≥ 15 points.
- Hematoma stability shown by a CT scan at least 6 hours after the diagnostic CT (hematoma volume increase < 5 ml by ABC/2 formula).
- Diagnostic CT scan should be obtained within 24 hours after the onset of symptoms. Cases with unclear onset time should be excluded.
- Randomization within 72 hours after diagnostic CT.
- Surgery should be performed within 72 hours after onset.
- SBP <180 mmHg maintained for 6 hours prior to randomization.
- Age between 18-70 years old.
- mRS score ≤ 1 in past medical history.
- Patients who are suitable and willing to be randomized to "puncture aspiration + urokinase" or conservative medical treatment.
Exclusion Criteria:
- Hematoma involves other structures such as the thalamus and midbrain.
- Mass effect or hydrocephalus due to intraventricular hemorrhage.
- Imaging-based diagnosis of cerebrovascular abnormalities such as ruptured aneurysm, arteriovenous malformation (AVM) and moyamoya disease as well as hemorrhagic transformation of ischemic infarct and recent recurrence (within 1 year) of cerebral hemorrhage.
- Manifestation of early stage cerebral herniation such as ipsilateral pupil changes and midline shift exceeding 1 cm.
- Patients with unsteady hematoma or with progression to intracranial hypertension syndrome.
- Patients with any irreversible coagulopathy or known coagulation disorders; platelet count <100,000; INR > 1.4.
- Patients requiring long-term use of anticoagulants.
- Patients taking dabigatran, apixaban and/or rivaroxaban (or similar drugs of the same category) before symptoms arise.
- Bleeding in other sites, including retroperitoneal, gastrointestinal, genitourinary or respiratory tract bleeding; superficial or skin surface bleeding mainly occurring in the vascular puncture site or transvenous approach (eg. arterial puncture, venous incision, etc. ) or in the recent surgical site.
- May be pregnant in the near future or already pregnant.
- Previously enrolled in this study.
- Participating in other interventional medical research or clinical trials at the same time. Patients enrolled in observational, natural history and/or epidemiological studies (without intervention) are eligible for this trial.
- Patients with an expected survival of less than 6 months.
- Patients with severe co-morbidity (including hepatic, renal, gastrointestinal, respiratory, cardiovascular, endocrine, immune and/or hematological disorders) which may affect the outcome assessment.
- Patients with mechanical heart valve. Biological valves are acceptable.
- Patients with risk of embolism (including a history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis or subacute bacterial endocarditis). Atrial fibrillation without mitral stenosis is acceptable.
- Investigators believe co-morbidities would be detrimental to the patient when the study begins.
- Patients difficult to follow up or with poor compliance due to various reasons (such as geographical and social factors, drug or alcohol abuse, etc.).
- Patient or his or her legal guardian/representative is unable or unwilling to give the written informed consent.
- Patient is in a condition that is not suitable for "puncture aspiration + urokinase" treatment.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Stereotactische chirurgie met behandeling met geneesmiddelen
|
stereotactic puncture and aspiration to evacuate basal ganglion hematoma with or without thrombolytic agent |
|
Sham-vergelijker: Guideline-based standard medical management
|
Guideline-based standard medical management |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Favorable Functional Outcome as Defined by the modified Rankin Scale (mRS) Score
Tijdsspanne: 180 days
|
Functional independence is defined as achieving a score of 0, 1, or 2 on the mRS. The mRS is a 7-point scale that measures the degree of disability or dependence in the daily activities of patients who have had a stroke. The scale ranges from 0 (no symptoms) to 6 (dead). |
180 days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
All-Cause Mortality
Tijdsspanne: 180 days
|
Time from randomization to death from any cause up to 180 days. |
180 days
|
|
Barthel Index (BI)
Tijdsspanne: 180 days
|
Functional status in activities of daily living (ADL) will be assessed using the Barthel Index (BI). The BI score ranges from 0 (completely dependent) to 100 (fully independent). |
180 days
|
|
Glasgow Outcome Scale-Extended (GOS-E) score
Tijdsspanne: 180 days
|
The GOS-E is an 8-point scale that categorizes global outcomes from Dead (1) to Upper Good Recovery (8). |
180 days
|
|
Residual Hematoma Volume
Tijdsspanne: 24 hours and one month
|
Absolute volume (in mL) of the hematoma remaining at 24 hours (± 6 hours) and at 1 month (± 7 days) post-intervention |
24 hours and one month
|
|
Length of Initial Hospital Stay
Tijdsspanne: one month
|
Total duration (in days) of the index hospitalization from admission to discharge (excluding transfers to other acute care facilities) |
one month
|
|
Total direct medical costs during the index hospitalization
Tijdsspanne: one month
|
Total direct healthcare costs related to the index ICH event incurred during the index hospitalization, assessed from a healthcare system perspective |
one month
|
Medewerkers en onderzoekers
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Cerebrovasculaire aandoeningen
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Vaatziekten
- Hart-en vaatziekten
- Pathologische processen
- Bloeding
- Basale ganglia-ziekten
- Intracraniële bloedingen
- Basale ganglia cerebrovasculaire ziekte
- Hersenbloeding
- Pathologische aandoeningen, tekenen en symptomen
- Basale ganglia bloeding
- Moleculaire mechanismen van farmacologische werking
- Fibrine-modulerende middelen
- Farmacologische acties
- Chemische acties en gebruik
- Therapeutisch gebruik
- Cardiovasculaire agenten
- Hematologische middelen
- Fibrinolytische middelen
Andere studie-ID-nummers
- 2018-222
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .